Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 18/20 | 0.51 |
| ▸ | PDE4A | P27815 | 16/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 16/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20042736 | 0.81 | NPY5R (0.36) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20042874 | 0.81 | NPY5R (0.36) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20042984 | 0.77 | NPY5R (0.35) | — | |
| SCHEMBL31614998 | 0.73 | MAP2K7 (0.32) | — | |
| SCHEMBL31614807 | 0.73 | MAP2K7 (0.32) | — | |
| SCHEMBL20042648 | 0.72 | CHRM3 (0.51) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20042840 | 0.70 | CHRM3 (0.43) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4423241 | 0.68 | CHRM3 (1.00) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20042895 | 0.66 | NPY5R (0.35) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4421504 | 0.65 | PDE10A (0.94) | CHRM3PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018066718-A1 | THERAPEUTIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-12 | — | — | WO | disclosed |